Literature DB >> 2898287

Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug.

T McGrath1, M S Center.   

Abstract

HL60 cells exhibiting a 140-fold increase in resistance to vincristine contain three surface membrane proteins with molecular weights of 210,000 (P210), 180,000 (P180), and 150,000 (P150) which are highly phosphorylated in vivo and in an in vitro system in the presence of Mn2+ and [gamma-32P]ATP. These phosphorylated proteins are either absent or present in very low levels in membranes of drug-sensitive cells. Growth of the vincristine-resistant isolate in the absence of drug results in a decrease in the level of resistance and a major reduction in the phosphorylation of P210 and P180. The phosphorylation of P150 is not altered in the revertant which still exhibits substantial levels of resistance. Further studies show that P210 and P180 are highly reactive with a monoclonal antibody against P-glycoprotein. These two proteins are present in only very low levels in revertant cells. The monoclonal antibody exhibits no reactivity with P150. In HL60 cells isolated for a 25-fold increase in vincristine resistance proteins reactive with P-glycoprotein monoclonal antibody are essentially absent. P150 is however highly phosphorylated in these cells. Additional experiments using lectin binding of 32P-labeled proteins demonstrates that P150 has properties distinct from P210 and P180. Analysis of drug uptake patterns in the vincristine-resistant isolates and the revertant shows that resistance is related to a reduced intracellular accumulation of drug. Reduced accumulation of vincristine is also found in HL60 cells isolated for resistance to Adriamycin. These cells are devoid of P-glycoprotein but contain phosphorylated P150. These results suggest that proteins P150, P180, and P210 may contribute to multidrug resistance in HL60 cells through a mechanism which involves reduced cellular accumulation of drug. P180 and P210 are structurally related whereas P150 is distinct from these two proteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898287

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter.

Authors:  S Paul; L M Breuninger; K D Tew; H Shen; G D Kruh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  P-glycoprotein structure and evolutionary homologies.

Authors:  J M Croop
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Comparison of Pgp- and MRP-mediated multidrug resistance in leukemia cell lines.

Authors:  Yu-Ping Gong; Ting Liu; Yong-Qian Jia; Li Qin; Cheng-Qi Deng; Ren-Yang Ou Yang
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

Review 5.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.

Authors:  R García del Moral; F O'Valle; M Andújar; M Aguilar; M A Lucena; J López-Hidalgo; C Ramírez; M T Medina-Cano; D Aguilar; M Gómez-Morales
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 7.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Alteration of C-MYB DNA binding to cognate responsive elements in HL-60 variant cells.

Authors:  C Gaillard; E Le Rouzic; C Créminon; B Perbal
Journal:  Mol Pathol       Date:  2002-10

9.  Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.

Authors:  C D Chiang; E J Song; V C Yang; C C Chao
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

Review 10.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.